Ackman's Pershing Square makes $3.3 billion bet on Valeant

Billionaire investor William Ackman has purchased a five percent stake in Valeant Pharmaceuticals (VRX.TO) (VRX.N), his hedge fund said on Monday, making him the Canadian drug company's fifth-largest stakeholder.

Read Full Article

Ackman's Pershing Square sees big payoff from Allergan deal

Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.

Read Full Article

Allergan near buyout of up to $65 billion to escape Valeant, Ackman: source

Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.

Read Full Article

Allergan says has been approached by another party about a deal

Botox maker Allergan Inc (AGN.N), fighting a hostile takeover bid by Valeant Pharmaceuticals Inc (VRX.TO), said on Monday it was approached about a potential transaction by another party, identified as Actavis Plc (ACT.N) by a source familiar with the situation.

Read Full Article

Top Allergan holder Paulson urges deal with Shire: sources

Allergan Inc (AGN.N) shareholder Paulson & Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc (SHP.L) as an alternative to a deal with hostile bidder Valeant Pharmaceuticals International Inc (VRX.TO), according to two people familiar with the matter.

Read Full Article

Actavis exits stake in China joint venture to Chiral

Dublin, Ireland-based pharmaceutical firm Actavis sold its stake in Chinese subsidiary Actavis (Foshan Pharmaceutical Co) for an undisclosed sum because of its limited presence in the country.

Read Full Article

Dublin-based Actavis Plc to divest some Western European operations to India's Aurobindo Pharma Ltd

India-based Aurobindo Pharma Ltd will be purchasing the generic drug operations of Dublin-based Actavis in seven countries in Western Europe in a deal worth around €30 million, Bloomberg reported.

Read Full Article

Ranbaxy sues Actavis over the production of a generic version of Absorica

A suit was filed in New Jersey District Court against Actavis by Ranbaxy Laboratories for its attempt to produce a generic version of Absorica.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics